Neurological and psychiatric Disorders Involved Intestinal Enteroendocrine Cells

Janine Margarita^*
*Correspondence: Janine Margarita, Department of Rehabilitation, University of South Australia, Magill, Australia, Email:

Introduction

Patients with neurological and psychological conditions have sharply increased in number in recent years. However, due to varied and ambiguous pathogenic pathways, effective therapies for many illnesses and disorders are scarce. Therefore, it is vitally necessary to do additional research into the molecular elements of the illness and to identify fresh targets for the creation of new therapeutic approaches. Studies at the systems level have suggested that the brain-gut axis and intestinal microbiota may have a role in the aetiology and control of neurological and psychiatric illnesses.In the last few decades, there has been a sharp rise in the number of people with neurological and psychiatric illnesses. Parkinson's disease (PD) patients have doubled in number during the past 25 years, according to World Health Organization (WHO) epidemiological statistics [1]. Additionally, according to the WHO's most current updates, 280 million individuals worldwide suffer from depression, while there are around a billion people worldwide who suffer from mental diseases [2,3]. However, due to the diverse illness aetiology and therapeutic targets, effective therapies for neurological and mental disorders are still scarce. Patients with depression or visceral discomfort, for instance, have been demonstrated to occasionally display resistance to therapy.

There is evidence that catecholamines contribute to TTS. TTS has frequently been documented to develop as a side effect of diseases such pheochromocytoma [4], acute subarachnoid haemorrhage [5], and acute thyrotoxicosis that have elevated catecholamine levels. Additionally, iatrogenic TTS happens during stress dobutamine echocardiography and following the administration of adrenaline. Wittstein et al. observed that the levels of adrenaline in 13 individuals with TTS were 10 to 20 times higher than normal and also greater than in STEMI. Additional proof comes from pre-clinical TTS models since adrenaline can effectively elicit TTS in rodent and primate animals. Though circulating catecholamine levels are incredibly transient, more recent investigations have failed to show higher catecholamine levels in TTS patients [6].

Discussion

Since over 60% of patients with lengthy COVID experience post-exertional malaise (PEM), which is identical to patients with myalgic encephalomyelitis, this topic is especially pertinent to those individuals. Exercise should be given in these situations with caution, and pacing or other cognitive approaches can be suggested (either in isolation or in combination with exercise therapy). Treatment of concomitant symptoms, particularly those with a nociplastic pain profile that might interact and perpetuate pain, such as sleep disturbances, tiredness, dyspnea, or autonomic disturbances, is also crucial for maximising treatment outcomes. In actuality, successful outcomes are less likely if related factors are not managed in addition to correcting underlying pain mechanisms (i.e., reducing central sensitization in the nociplastic post-COVID pain phenotype).

Conclusion

Patients who have recovered from moderate to severe ARDS-related COVID-19 damage have irreversible functional deficits. In the post-discharge pulmonary rehabilitation, exercise is essential. Despite being secure and the standard form of training, CONC exercises provide exercise-limiting cardiovascular stress, dyspnea, and fatigue. Therefore, lowered tolerance and training compliance can significantly reduce prospective advantages. ECC, on the other hand, is a cutting-edge form of training that is often employed by athletes but much less frequently in therapeutic settings. Recent studies show that COPD patients who exercise with ECC as opposed to CONC experience significantly greater gains in functional capacity and muscle mass as well as fewer complaints of fatigue and dyspnea. However, there are few outpatient data following COVID-19.

Conflict of Interest

None.

References

1. Hanson, Karen A., Edward V. Loftus Jr, W. Scott Harmsen and Nancy N. Diehl et al. "Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case–control study." Inflamm Bowel Dis 15 (2009): 772-777.

[Google Scholar], [Crossref], [Indexed at]

2. Drossman, Douglas A., Carolyn B. Morris, Hollie Edwards and Christina ED Wrennall, et al. "Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome." J Gastroenterol ACG 107(2012): 1426-1440.

[Google Scholar], [Crossref], [Indexed at]

3. Mueller, Timothy I., Andrew C. Leon, Martin B. Keller and David A. Solomon, et al. "Recurrence after recovery from major depressive disorder during 15 years of observational follow-up." Am J Psychiatry 156(1999): 1000-1006.

[Google Scholar], [Crossref]

4. Trivedi, Madhukar H., Maurizio Fava, Stephen R. Wisniewski and Michael E. Thase, et al. "Medication augmentation after the failure of SSRIs for depression." N Engl J Med 354 (2006): 1243-1252.

[Google Scholar], [Crossref], [Indexed at]

5. Tolhurst, Gwen, Helen Heffron, Yu Shan Lam and Helen E. Parker, et al. "Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein–coupled receptor FFAR2." Diabetes 61(2012): 364-371.

[Google Scholar], [Crossref]

6. Psichas, A., M. L. Sleeth, K. G. Murphy and L. Brooks, et al. "The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents." Int J Obes 39(2015): 424-429.

[Google Scholar], [Crossref]